CDiddy, As a point of reference, (this is not a

CDiddy,

As a point of reference, (this is not an apples to apples comparison) the tree main advances in ARDS treatment have been:

2000 Low Tidal volume (mortality reduced from 40% to 31%)

2010 Paralysis (mortality reduced from 41% to 31%)

2013 Prone Positioning (33% to 16%)

This is for all ARDS. Now, with coronavirus, is possible that the inflammation is such that the condition is more severe, however, anything that reduces the mortality in about 10% will be welcomed (has been welcomed and accepted by the medical community).

I suspect that, as Leronlimab is addressing the root cause (inflammation) it has a good shoot at being more effective than the palliative techniques depicted above.

This imo, I do not know what will be accepted as a successful outcome. However, Dr. Patterson's company has extensive diagnostic testing capabilities to analyze the results and draw conclusions on the effectiveness (or lack) of the treatment. He is receiving samples from the patients and I am sure he is analyzing lots of parameters. He mentioned he was carrying out a immunological profile.